18
Participants
Start Date
April 28, 2020
Primary Completion Date
February 15, 2022
Study Completion Date
August 26, 2022
Retifanlimab
INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.
IRCCS Ospedale San Raffaele, Milan
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano., Milan
AUSL Reggio Emilia, Reggio Emilia
Hospital de la Santa Creu i Sant Pau, Barcelona
ICO-Hospitalet, L'Hospitalet de Llobregat
Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria
Hospital 12 de octubre, Madrid
Hospital Clínico San Carlos, Madrid
Hospital Virgen de la Arrixaca, Murcia
Hospital Universitari Son Espases, Palma de Mallorca
Hospital Virgen del Rocío, Seville
Instituto Valenciano de Oncología, Valencia
Hospital Miguel Servet, Zaragoza
Collaborators (1)
Incyte Biosciences International Sàrl
INDUSTRY
MedSIR
OTHER